Company: BDRX
Filing Date: 2025-01-08
Form Type: 424B3
Source: 0001214659-25-000303
Chunk: 98

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-08
Form: 424B3
Chunk 98
---
 the Company makes a general assignment of all or substantially all of its
assets for the benefit of creditors; or the Company or any Subsidiary of the Company shall fail to pay, or shall state that it is unable
to pay, or shall be unable to pay, its debts generally as they become due; or the Company or any Subsidiary of the Company shall call
a meeting of its creditors with a view to arranging a composition, adjustment or restructuring of its debts; or the Company or any Subsidiary
of the Company shall by any act or failure to act expressly indicate its consent to, approval of or acquiescence in any of the foregoing;
or any corporate or other action is taken by the Company or any Subsidiary of the Company for the purpose of effecting any of the foregoing;

(iii) The Company
or any Subsidiary of the Company shall default beyond applicable grace and cure periods in any of its obligations under any other debenture
or any, mortgage, credit agreement or other facility, indenture agreement, factoring agreement or other instrument under which there may
be issued, or by which there may be secured or evidenced any indebtedness for borrowed money or money due under any long term leasing
or factoring arrangement of the Company or any Subsidiary of the Company in an amount exceeding $100,000, whether such indebtedness now
exists or shall hereafter be created and such default shall result in such indebtedness becoming or being declared due and payable;

(iv) The ADSs shall
cease to be quoted or listed for trading, as applicable, on any Primary Market as a result of failure to comply with the listing standards
thereof or a voluntary delisting for a period of five (5) consecutive Trading Days;

(v) The Company’s
failure to timely file with the Commission any Periodic Report on or before the due date of such filing as established by the Commission,
it being understood, for the avoidance of doubt, that due date includes any permitted filing deadline extension under the Exchange Act;

(vi) Any representation
or warranty made by the Company on Annex A hereto or made or deemed to be made by the Company in or in connection with any Transaction
Document, or any waiver hereunder or thereunder, shall prove to have been incorrect in any material respect (or, in the case of any such
representation or warranty already qualified by materiality, such representation or warranty shall prove to have been incorrect) when
made